Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients with lung cancer.

In May, Vitrolife announced that Bronwyn Brophy O'Connor had decided to step down as President and CEO to take up the same ...

AstraZeneca’s experimental cancer treatment sone-ve delivered longer survival than analysts had expected in a phase III trial ...

MEMBER ANNOUNCEMENT - Gruber A/S will join the Danish Pavilion at COMPAMED in Düsseldorf on 16–19 November 2026, with a focus ...

Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government ...

Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, ...

New treatments for ALS are raising hopes among researchers. “The earlier a patient receives targeted gene therapy, the ...

Zealand Pharma has entered into a partnership with American biotech company Generate Biomedicines to develop protein based ...

Biotech company Moderna fell nearly 18 percent on the stock market after study data on the company’s mRNA-based cancer ...

The Swedish medtech company Inossia, which is developing an additive for bone cement, has completed an oversubscribed SEK 88 ...

Based in Lund, Spago Nanomedical is developing Tumorad, a radionuclide therapy currently being evaluated in a Phase I study ...

Pfizer has previously announced a major cost-cutting programme. Now, reports have emerged of job losses at several of the pharmaceutical giant's manufacturing sites in Europe and the US.